Mechanism of Action
YK-11 activates androgen receptors and simultaneously induces production of Follistatin, a natural myostatin inhibitor. Myostatin limits muscle fiber growth — inhibiting it in animal models produces dramatic muscle hypertrophy. The in vitro data is compelling. The translation to human outcomes is completely unestablished as no human trials exist.
Ester Profile
Non-steroidal oral compound with a steroid-like structure that makes it chemically distinct from most SARMs. Short half-life of 6-10 hours requires twice or three times daily dosing. No ester.
How It's Used in Fitness
YK-11 is used in performance settings by individuals specifically seeking the myostatin inhibition effect on top of the androgen receptor activity. The theoretical appeal is significant — removing the natural ceiling on muscle growth is a compelling concept. In practice, the in vitro myostatin inhibition data has not been validated in human use, and the actual performance effects reported by users are consistent with androgen receptor agonism rather than anything uniquely attributable to myostatin inhibition.
Stacking Context
YK-11 appears in stacks with other SARMs, most commonly RAD-140 or LGD-4033, by users who want to add the theoretical myostatin inhibition to an existing anabolic protocol. It is not a base compound. Given the complete absence of human safety data, combining it with other compounds makes the risk assessment even more complex.
Medical Use
- No approved medical use
- No completed human trials of any phase
- All data is in vitro or animal-based
Side Effects
- Testosterone suppression — degree unknown, assumed significant based on AR agonism
- Liver enzyme elevation — suspected based on structural characteristics
- Unknown long-term safety profile — no human trial data exists
- Hair loss from androgenic activity
- Joint pain reported
- Unknown interaction profile with other compounds
What Actually Goes Wrong
YK-11 has the least human safety data of any commonly circulated performance compound. There are no human trials, no established safe dose ranges, no established contraindications, and no long-term safety data of any kind. The compounds structural similarity to steroids means it likely carries the suppression and hepatic stress associated with that class, but the exact risk profile is genuinely unknown. Using YK-11 is accepting a risk profile that cannot currently be quantified.
Detection Window
WADA bans all SARMs. Specific YK-11 detection methodology is limited given the novelty of the compound.
The myostatin inhibition concept is real and scientifically interesting. YK-11 as a delivery mechanism for that concept in humans is a leap that the data does not support. Every compound on this list has some human data — clinical trials, case reports, or decades of documented use. YK-11 has none. That is not a regulatory technicality. It means the risk profile is genuinely unknown in a way that is categorically different from other compounds on this list.